Compound · clinical trials

Nmdae clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 11 trials in our China and Taiwan registers that name Nmdae as an intervention. Synced 10 Nov 2026

11Current trials

11Recruiting now

1Lead sponsor

2Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Nmdae is named as an intervention in 11 current clinical trials in our China and Taiwan registers. 11 are recruiting patients now. All registered phases are Phase 2. The lead sponsor is China Medical University Hospital. The most-studied condition is Schizophrenia.

Patient leaflets for Nmdae

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting11100%

Trials by phase

Phase 211100%

Clinical trials of Nmdae

11 trials

Study	Phase	Status	Lead sponsor	Registers
NMDA Modulation in Major Depressive Disorder NCT04637620 · ClinicalTrials.gov ↗ · Major Depressive Disorder	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan
Monotherapy of an NMDA Enhancer for Schizophrenia NCT04745143 · ClinicalTrials.gov ↗ · Schizophrenia	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia NCT04917302 · ClinicalTrials.gov ↗ · Schizophrenia	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia NCT04959201 · ClinicalTrials.gov ↗ · Schizophrenia	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer NCT05052853 · ClinicalTrials.gov ↗ · Prodromal Schizophrenia	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder NCT05136755 · ClinicalTrials.gov ↗ · Major Depressive Disorder	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia NCT05240976 · ClinicalTrials.gov ↗ · Schizophrenia	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder NCT05977023 · ClinicalTrials.gov ↗ · Bipolar I Disorder	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia NCT06021197 · ClinicalTrials.gov ↗ · Schizophrenia	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia NCT06574360 · ClinicalTrials.gov ↗ · Schizophrenia	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan
Sex Differences in NMDA-enhancing Treatment of Schizophrenia NCT07122895 · ClinicalTrials.gov ↗ · Schizophrenia	Phase 2	Recruiting	China Medical University Hospital	China, Taiwan

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Nmdae

4 conditions

Schizophrenia7 Major Depressive Disorder2Prodromal Schizophrenia1Bipolar I Disorder1

By country register

Register	Trials	Recruiting
Clinical trials in China	11	11
Clinical trials in Taiwan	11	11

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Nmdae trials

How many clinical trials are testing Nmdae?

11 current trials in our China and Taiwan registers name Nmdae as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Nmdae trials recruiting patients?

Yes. 11 of the 11 trials are recruiting: 11 with sites in China and 11 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Nmdae clinical trials?

The lead sponsor is China Medical University Hospital. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nmdae works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nmdae works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nmdae (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.